GIUNTA, ALESSANDRO
 Distribuzione geografica
Continente #
NA - Nord America 11.350
AS - Asia 1.661
EU - Europa 1.632
SA - Sud America 220
AF - Africa 78
OC - Oceania 37
Totale 14.978
Nazione #
US - Stati Uniti d'America 11.276
SG - Singapore 586
CN - Cina 345
IT - Italia 229
BR - Brasile 185
RU - Federazione Russa 182
DE - Germania 167
FR - Francia 156
HK - Hong Kong 152
GB - Regno Unito 133
SE - Svezia 131
UA - Ucraina 125
VN - Vietnam 124
IE - Irlanda 122
FI - Finlandia 96
IN - India 93
CA - Canada 51
JP - Giappone 49
KR - Corea 44
TR - Turchia 44
NL - Olanda 43
PL - Polonia 41
PK - Pakistan 39
AU - Australia 36
ES - Italia 36
ID - Indonesia 36
BE - Belgio 33
EG - Egitto 30
TW - Taiwan 28
CH - Svizzera 27
HU - Ungheria 18
IQ - Iraq 17
PH - Filippine 16
MX - Messico 15
ZA - Sudafrica 15
AR - Argentina 14
IR - Iran 14
RO - Romania 13
IL - Israele 12
AT - Austria 11
BD - Bangladesh 11
GR - Grecia 10
NG - Nigeria 10
PT - Portogallo 10
EE - Estonia 9
LT - Lituania 9
EC - Ecuador 8
UZ - Uzbekistan 8
MA - Marocco 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
DK - Danimarca 5
HR - Croazia 5
JO - Giordania 5
KG - Kirghizistan 5
MY - Malesia 5
TH - Thailandia 5
BJ - Benin 4
ET - Etiopia 4
JM - Giamaica 4
KW - Kuwait 4
NO - Norvegia 4
SA - Arabia Saudita 4
CO - Colombia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
DZ - Algeria 2
LB - Libano 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
GP - Guadalupe 1
GQ - Guinea Equatoriale 1
KE - Kenya 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
NA - Namibia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 14.978
Città #
Wilmington 3.078
Houston 2.795
Woodbridge 2.331
Fairfield 409
Singapore 366
Ashburn 322
Chandler 236
Cambridge 168
Ann Arbor 167
Seattle 158
San Jose 143
Hong Kong 126
Beijing 108
Dearborn 103
Dublin 98
Rome 97
Medford 86
Jacksonville 85
New York 76
Santa Clara 66
The Dalles 57
Helsinki 55
Los Angeles 49
Lawrence 39
Council Bluffs 36
Tokyo 35
Moscow 32
Lauterbourg 31
Munich 31
Dallas 30
Zhengzhou 30
Hanoi 28
Jönköping 28
Redwood City 28
Ho Chi Minh City 26
San Diego 25
Stockholm 25
Shanghai 24
Warsaw 21
Jakarta 19
Buffalo 18
London 18
Boardman 17
Frankfurt am Main 17
Milan 17
Denver 16
Montreal 16
São Paulo 14
Duncan 13
Hefei 13
Menlo Park 13
Boston 12
Brussels 12
Norwalk 12
Redondo Beach 12
Chicago 11
Lahore 11
Nanjing 11
Seoul 11
Atlanta 10
Budapest 10
Central 10
Delhi 10
Hangzhou 10
Hyderabad 10
Salcedo 10
Taipei 10
Toronto 10
Cairo 9
Johannesburg 9
Lappeenranta 9
Ottawa 9
Sydney 9
Ankara 8
Da Nang 8
Haiphong 8
Kraków 8
Kunming 8
Lagos 8
Madrid 8
New Delhi 8
Palo Alto 8
San Francisco 8
Baghdad 7
Bengaluru 7
Bucharest 7
Dong Ket 7
Esslingen am Neckar 7
Lima 7
Naples 7
Nuremberg 7
Paris 7
Phoenix 7
Tallinn 7
Utrecht 7
Amsterdam 6
Brisbane 6
Chennai 6
Düsseldorf 6
Guayaquil 6
Totale 12.260
Nome #
European S3-guidelines on the systemic treatment of psoriasis vulgaris 1.645
Loss of CRABP-II Characterizes Human Skin Poorly Differentiated Squamous Cell Carcinomas and Favors DMBA/TPA-Induced Carcinogenesis 695
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 479
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 466
New topical treatments for psoriasis 456
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 455
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 436
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management 433
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 419
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 419
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study 417
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 409
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 407
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 403
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 394
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 383
Dermatitis artefacta in sporadic sclerodermoid hepatitis C virus-associated porphyria cutanea tarda 371
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 368
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 366
Histopathology of the skin in rheumatic diseases 362
Rapid, persistent, and simultaneous remission of urticaria and severe atopic dermatitis after treatment with omalizumab 361
Long-lasting remission of pemphigus vulgaris treated with rituximab 360
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 358
Treatment of Hailey-Hailey disease with topical calcitriol 338
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 338
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 332
Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study 313
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 302
null 287
Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis 274
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections 272
The economic impact of biosimilars in Italy: a scenario analysis 245
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 242
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 186
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 177
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 157
Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting 119
Ixekizumab in nail psoriasis 116
High expression of cellular retinol binding protein-1 in lung adenocarcinoma is associated with poor prognosis 112
Connective tissue nevus in Marfan syndrome successfully treated with intralesional steroid injections 106
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 94
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 82
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis) 76
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 74
Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution 67
Effectiveness of ixekizumab in elderly patients for the treatment of moderate-to-severe psoriasis: results from a multicenter, retrospective real-life study in the Lazio region 55
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis) 53
Totale 15.279
Categoria #
all - tutte 35.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.393


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021129 0 0 0 0 0 0 0 0 0 0 84 45
2021/2022688 28 88 50 66 22 52 49 44 55 47 60 127
2022/2023768 64 75 37 93 61 112 66 63 91 23 39 44
2023/2024488 48 26 28 31 39 99 49 52 12 22 23 59
2024/20251.126 46 233 115 88 31 69 82 58 91 101 124 88
2025/20261.754 181 90 264 201 167 74 225 210 189 143 10 0
Totale 15.279